RESEARCH

NANEXA: Clinical milestones align ahead of phase Ib/II and licensing push

Analys, Research

Nanexa continues to strengthen the foundation for the upcoming Phase Ib/II study in the NEX-22...

Read More

PROLIGHT: Positive results from the pre-clinical validation study de-risk the full clinical validation

Analys, Research

Following the many recent grants, notices of allowance and intention to grant patents in Europe and...

Read More

CINDRIGO HOLDINGS: Lower risk with first revenues, Germany secured and LSE Main Market listing

Research

Johan Widmark | 2025-03-10 10:30  Read the report in PDF here With production now commenced at the...

Read More

TALLINK: Free cash flow support dividends

Okategoriserade, Research

RESEARCH COLLABORATION WITH ENLIGHT RESEARCH  Q4 profit was below forecast but the declared...

Read More

NANEXA: Targeting treatment of first patient in phase Ib/II with NEX-22 before year-end

Analys, Research

Nanexa’s Q4 report did not reveal much new, although the conference call provided welcome clarity...

Read More

CRUNCHFISH: Still in the running for a one billion-user Digital Cash market

Analys, Research

Johan Widmark | 2025-02-14 08:00  READ FULL REPORT IN PDF HERE Small signs pointing towards a...

Read More

NANEXA: Financing secured into 2026 to drive NEX-22 development

Analys, Research

Johan Widmark | 2025-01-27 08:00  READ FULL REPORT HERE IN PDF With the directed issue of units...

Read More

GRANGEX: PEA confirmns robust economics for Sydvaranger – mapping the road to financial close in H2’25

Analys, Research

With the release of a Preliminary Economic Assessment (PEA) for the restart of the Sydvaranger...

Read More